Abstract

BackgroundSchizophrenia is a widespread and debilitating mental disorder. However, the underlying molecular mechanism of schizophrenia remains largely unknown and no objective laboratory tests are available to diagnose this disorder. The aim of the present study was to characterize the alternations of glucose metabolites and identify potential diagnostic biomarkers for schizophrenia.MethodsGas chromatography/mass spectrometry based targeted metabolomic method was used to quantify the levels of 13 glucose metabolites in peripheral blood mononuclear cells (PBMCs) derived from healthy controls, schizophrenia and major depression subjects (n = 55 for each group).ResultsThe majority (84.6%) of glucose metabolites were significantly disturbed in schizophrenia subjects, while only two (15.4%) glucose metabolites were differently expressed in depression subjects relative to healthy controls in both training set (n = 35/group) and test set (n = 20/group). Antipsychotics had only a subtle effect on glucose metabolism pathway. Moreover, ribose 5-phosphate in PBMCs showed a high diagnostic performance for first-episode drug-naïve schizophrenia subjects.ConclusionThese findings suggested disturbance of glucose metabolism may be implicated in onset of schizophrenia and could aid in development of diagnostic tool for this disorder.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-015-0540-y) contains supplementary material, which is available to authorized users.

Highlights

  • Schizophrenia is a widespread and debilitating mental disorder

  • As an area under ROC curve (AUC) of 1 indicates perfect discrimination, these results demonstrated that ribose 5-phosphate in peripheral blood mononuclear cells (PBMCs) may be a potential biomarker for first-episode drug-naïve schizophrenia subjects

  • We found that majority of glucose metabolites in PBMCs were disturbed in schizophrenia subjects, which was in contrast to the findings of depression subjects

Read more

Summary

Introduction

Schizophrenia is a widespread and debilitating mental disorder. The aim of the present study was to characterize the alternations of glucose metabolites and identify poten‐ tial diagnostic biomarkers for schizophrenia. Schizophrenia is a multifaceted and devastating mental disorder affecting up to 1% of the general population [1]. It causes progressive functional decline, lifelong disability and tremendous socioeconomic burden for patients [2, 3]. Quantifiable differences in metabolite patterns provide valuable clues to uncover the mechanism and develop diagnostic biomarkers for psychiatry disorders [5, 6]. We have identified diagnostic metabolite biomarkers for major depression and bipolar disorder [9, 10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call